Transplant rejection clues sought in patient proteins
NCT ID NCT01163578
First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study is looking at proteins in the blood and tissues of people who have received an organ or bone marrow transplant. The goal is to learn more about how anti-rejection drugs work and why some people reject their transplant while others do not. Researchers will follow 1,200 patients of all ages at the University of Pittsburgh Medical Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to monitor and treat organ rejection after transplant.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE MARROW TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Pittsburgh of UPMC
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
- Artificial intelligence could help prevent transplant complications by personalizing drug dosing
- New study to test antifungal drug safety in organ transplant patients
- Can a dialysis-like treatment save kids with lung failure after transplant?
- Can a wearable glucose sensor be trusted in the ICU? new study aims to find out
- New drug cocktail aims to tame deadly transplant complication